金吾财讯 | 德国Evotec SE 引起了纳斯达克上市生物科技公司 Halozyme Therapeutics Inc. (HALO)的收购兴趣，这笔交易将使这家德国药物开发商的估值达到 20 亿欧元（21 亿美元）。公司已提交了一份不具约束力的收购要约，以每股 11 欧元的价格收购 Evotec。这比 Evotec 周四的收盘价高出约 27%。
Halozyme 首席执行官 Helen Torley 在声明中表示，收购 Evotec 将使公司的增长延续到下一个十年甚至更远。她表示，“凭借规模的扩大、深厚的产品线和多样化的产品，我们将成为生物制药行业极具吸引力的战略合作伙伴。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.